SecurityAQSZF / Aequus Pharmaceuticals Inc. (007636103)
IndustryCannabis and Medical Marijuana Dispensaries
Institutional Owners0

Institutional Stock Ownership and Shareholders

Aequus Pharmaceuticals Inc. (OTC:AQSZF) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Aequus Pharmaceuticals Inc. (OTC:AQSZF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
AQSZF: Aequus Pharmaceuticals Analysis and Research Report

2018-04-30 - Asif

Overview Aequus is a growing specialty pharmaceutical company, with a foundation built on improving drug delivery of existing medications. Aequus has a diversified portfolio of internally developed clinical and preclinical stage reformulated products as well as a number of commercial stage, third party products that fulfill an identified unmet medical need. The company's development pipeline is focused on advancing products in specialty therapeutic areas with a goal of addressing the need for improved medication adherence through enhanced delivery systems. Aequus intends to commercialize its internal programs in Canada alongside its current portfolio of marketed established medicines and will look to form strategic commercial partnerships for these programs in other markets that would maximize the reach of its product candidates worldwide. The company's most recent addition to the development pipeline was a long-acting form of medical cannabis, where there is a high need for...

CUSIP: 007636103